The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).
 
Kazuhiro Ezaka
No Relationships to Disclose
 
Goro Nakayama
No Relationships to Disclose
 
Hiroyuki Yokoyama
No Relationships to Disclose
 
Takanori Matsui
No Relationships to Disclose
 
Shinichi Umeda
No Relationships to Disclose
 
Yuki Sunagawa
No Relationships to Disclose
 
Kenta Murotani
No Relationships to Disclose
 
Yuichi Ando
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Ajinomoto; Asahi Kasei; Chugai Pharma; Covidien/Medtronic; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Olympus; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - abbott Japan (Inst); Abbvie (Inst); Ajinomoto (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Covidien (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Japan Blood Products Organization (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Lilly Japan (Inst); Maruho (Inst); Merck (Inst); Mitsubishi Tanabe Pharma (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst); Tsumura & Co. (Inst); Yakult Pharmaceutical (Inst); Yoshindo (Inst)